![](https://endpts.com/wp-content/uploads/2018/10/albert-bourla-endpts-tile-credit-AP.jpg)
Albert Bourla, Pfizer CEO (AP Images)
Covid-19 pill could add another $15-25B to Pfizer's already torrid pandemic cash flow — analyst
If you thought Pfizer was raking it in with megablockbuster sales of its BioNTech-partnered Covid-19 vaccine — last projected at $36 billion for 2021 — think again …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.